Helen Cristina Stankiewicz Karita

Helen Cristina Stankiewicz Karita

Auto-generated profile, based on publicly available information

Helen Cristina Stankiewicz Karita

Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, CA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
TDTracy Q. Dong
Tracy Q. Dong
CJChristine Johnston
Christine Johnston
KNKathleen M. Neuzil
Kathleen M. Neuzil
MPMichael K. Paasche-Orlow
Michael K. Paasche-Orlow
EBElizabeth R. Brown
Elizabeth R. Brown
Since December 2019, COVID-19 has caused more than 5 million deaths worldwide.1 Despite the substantial advancement in public health prevention approaches and the deployment of vaccines, the pandemic continues because less than 50% of the global population has received any vaccine doses.2 Furthermore, the emergence and spread of novel variants of concern have compelled global attention because of increased transmissibility and potential virulence.3-7 Novel variants, including the Delta variant, have outcompeted the wild-type virus and the earlier-identified variants as the dominant circulating strain in the US and many other countries.3,5,8,9

1 March 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
RBRuanne V Barnabas
Ruanne V Barnabas
EBElizabeth R Brown
Elizabeth R Brown
ABAnna Bershteyn
Anna Bershteyn
HKHelen C Stankiewicz Karita
Helen C Stankiewicz Karita
CJChristine Johnston
Christine Johnston
JBJared M Baeten
Jared M Baeten
Clinical trials have ruled out a role of hydroxychloroquine in the treatment of COVID-19, but it has been hypothesized that hydroxychloroquine's activity against SARS-CoV-2 in the laboratory sugges... Visual Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection Clinical trials have ruled out a role of hydroxychloroquine in the treatment of COVID-19, but it has been... Background: Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strat...

8 May 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
OKOlivia S. Kates
Olivia S. Kates
CFCynthia Fisher
Cynthia Fisher
HSHelen C. Stankiewicz-Karita
Helen C. Stankiewicz-Karita
ASAmanda K. Shepherd
Amanda K. Shepherd
ECE. Chandler Church
E. Chandler Church
ALAjit Limaye
Ajit Limaye
With the rapidly expanding pandemic of SARS-CoV-2, there is concern that solid organ transplant recipients will be particularly vulnerable to infection and may experience a more severe clinical course. We report four cases of COVID-19 in solid organ transplant recipients including recipients of kidney, liver, lung, and heart transplants. We describe each patient's medical history including transplantation history, their clinical presentation and workup, and their course from diagnosis to either hospital discharge or to improvement in symptoms. These reports demonstrate a range of symptoms, clinical severity, and disease course in solid organ transplant recipients with COVID-19, including two hospitalized patients and two patients managed entirely in the outpatient setting.

1 June 2018 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KBKristina L Bajema
Kristina L Bajema
HKHelen C Stankiewicz Karita
Helen C Stankiewicz Karita
MTMark W Tenforde
Mark W Tenforde
SHStephen E Hawes
Stephen E Hawes
RHRenee Heffron
Renee Heffron
Hepatitis B virus (HBV) infection in pregnancy has been associated with risk of adverse maternal and infant outcomes in highly endemic settings, but this association is not well characterized in the United States. We conducted a retrospective population-based cohort study in Washington State using linked birth certificate and hospital discharge records from 1992–2014. Among pregnant women with hepatitis B (n = 4391) and a hepatitis B–negative group (n = 22 410), we compared the risk of gestational diabetes, pre-eclampsia, eclampsia, placenta previa, preterm delivery, low birthweight, small for gestational age, and large for gestational age using multivariate logistic regression. Hepatitis B–infected pregnant women were more likely to be Asian (61% vs 8%, P < .001), foreign-born (76% vs 23%, P < .001), and older in age (77% vs 64% ≥26 years, P < .001). They were less commonly overweight or obese (33% vs 50%, P < .001). There was a lower risk of small for gestational age infants among HBV-infected women (adjusted RR [aRR], 0.79; 95% confidence interval [CI], 0.67–0.93). The risk of other adverse outcomes was not significantly different between hepatitis B–infected and –negative women (gestational diabetes: aRR, 1.11; 95% CI, 0.92–1.34; pre-eclampsia: aRR, 1.06; 95% CI, 0.82–1.35; eclampsia: aRR, 2.31; 95% CI, 0.90–5.91; placenta previa: aRR, 1.16; 95% CI, 0.35–3.84; preterm delivery: aRR, 1.15; 95% CI, 0.98–1.34; low birth weight: aRR, 1.08; 95% CI, 0.90–1.29; large for gestational age: aRR, 1.01; 95% CI, 0.82–1.24). In a low-burden setting in the United States, hepatitis B infection was not associated with adverse pregnancy outcomes.

5 April 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
KHKirsten Hauge
Kirsten Hauge
AMAmalia Magaret
Amalia Magaret
CMConstance Mao
Constance Mao
JSJeffrey Schouten
Jeffrey Schouten
AWAnna Wald
Anna Wald
Persistent infection with oncogenic human papillomavirus (HPV) has been linked to 70% of vulvar and 90% of anal cancers, causing more than 45 000 cases worldwide each year.1 In the United States, more than 10 000 cases are diagnosed annually, and most are HPV-16 related.2 Incidence rates of anal and vulvar cancer have increased over the past decades in the United States, particularly among high-risk groups.3 Specifically, among US HIV-infected men who have sex with men (MSM), the incidence of anal cancer (78 of 100 000) currently exceeds the incidence of cervical cancer in sub-Saharan Africa (55 of 100 000 women).4,5 Locally invasive anal and vulvar cancers are associated with 48% and 59% 5-year survival, respectively.6

5 December 2019 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
AMAmalia Magaret
Amalia Magaret
MHMeei-Li Huang
Meei-Li Huang
KJKeith R. Jerome
Keith R. Jerome
QFQuinne Feng
Quinne Feng
AWAnna Wald
Anna Wald
Objective: This study aimed to assess quantitative human papillomavirus (HPV) type 16 and HPV18 detection in oral rinses obtained in dental offices in Seattle, Washington. Methods: We evaluated oral rinses collected during dental visits from 2016 to 2018. Multiplex TaqMan quantitative polymerase chain reaction was used to determine HPV16 and HPV18 viral load (VL). Results: Of 15,313 persons, 152 (1%) had detectable oral HPV16/18. Men were at higher risk of oral HPV16/18 infection than women (1.6% vs. 0.6%; odds ratio, 3.2; 95% confidence interval, 2.1–4.4). Compared with women, men with HPV16 were older (median, 55 vs. 48 years; P < 0.001) and had higher VL (39.7 vs. 1.1 copies/mL, P < 0.001). Of 39 with HPV16 at baseline and a second oral rinse, 13 remained positive at subsequent rinse; of 8 with HPV18 at baseline, 2 remained positive at subsequent rinse. Persons with consecutive positive test results were all men and had higher baseline VL compared with those with first positive and second negative samples. Conclusion: Oral rinse is an acceptable method of HPV testing, and persons are interested in testing. Overall HPV16/18 prevalence was low, and detection was more frequent among men than women, especially at higher copy numbers. HPV16 persistence was more common in men with high VL at baseline test. Future studies are needed to evaluate the feasibility of an effective secondary prevention strategy for oropharyngeal cancer using quantitative oral HPV detection.